# Table of Contents

- **HEADER** .................................................. 1
- **ABSTRACT** ............................................... 1
- **PLAIN LANGUAGE SUMMARY** ............................... 2
- **BACKGROUND** ........................................... 2
- **OBJECTIVES** ............................................ 3
- **METHODS** ............................................... 3
- **RESULTS** ................................................ 5
- **DISCUSSION** ............................................. 5
- **AUTHORS’ CONCLUSIONS** ................................. 5
- **ACKNOWLEDGEMENTS** .................................... 6
- **REFERENCES** ............................................. 6
- **CHARACTERISTICS OF STUDIES** ......................... 7
- **DATA AND ANALYSES** .................................... 9
- **APPENDICES** ............................................. 9
- **WHAT’S NEW** ............................................ 9
- **HISTORY** ................................................ 10
- **CONTRIBUTIONS OF AUTHORS** ......................... 10
- **DECLARATIONS OF INTEREST** .......................... 10
- **INDEX TERMS** .......................................... 10
Influenza vaccine for children and adults with bronchiectasis

Christina C Chang¹, Peter S Morris², Anne B Chang³

¹Infectious Diseases Unit, The Alfred Hospital, Monash University, Prahran, Australia. ²Ear Health and Education Unit, Menzies School of Health Research, Royal Darwin Hospital, Block 4, Darwin, Australia. ³Royal Children's Hospital, Brisbane and Menzies School of Health Research, CDU, Darwin, Queensland Children's Respiratory Centre and Queensland Children's Medical Research Institute, Brisbane, Australia

Contact address: Christina C Chang, Infectious Diseases Unit, The Alfred Hospital, Monash University, Commercial Road, Prahran, Victoria, 3181, Australia. ccchang339@hotmail.com. christina.chang@med.monash.edu.au.

Editorial group: Cochrane Airways Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 9, 2010.
Review content assessed as up-to-date: 19 July 2010.

Citation: Chang CC, Morris PS, Chang AB. Influenza vaccine for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006218. DOI: 10.1002/14651858.CD006218.pub2.

Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Bronchiectasis is a major cause of respiratory morbidity especially in developing countries. In affluent countries, bronchiectasis is increasingly recognised in certain subsections of communities (e.g., Aboriginal communities) as well as a coexistent disease/comorbidity and disease modifier in respiratory diseases such as COPD (reported rates of 29-50% in adults). Respiratory exacerbations in people with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Current recommendations for inactivated influenza vaccination includes adults aged 65 years and over, those in residential care and health care workers and also all adults and children with chronic illness, particularly cardiac and pulmonary diseases.

Objectives

To evaluate the effectiveness of influenza vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline

Search methods

The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of influenza were also contacted. The latest searches were performed in July 2010.

Selection criteria

All randomised controlled trials with at least one annual influenza vaccine involving children or adults with bronchiectasis.

Data collection and analysis

Results of searches were reviewed against pre-determined criteria for inclusion. It was planned that two independent reviewers selected, extracted and assessed data for inclusion.

Main results

No eligible trials were identified and thus no data were available for analysis.
Authors’ conclusions

There is neither evidence for, nor against, routine annual influenza vaccination for children and adults with bronchiectasis.

**PLAIN LANGUAGE SUMMARY**

**Influenza vaccine for children and adults with bronchiectasis**

In many countries, influenza vaccination is an accepted part of routine immunisation recommendations particularly in persons 65 years and over, those in long-term care facilities and also adults and children with chronic illnesses including those with bronchiectasis. In this review however, our search for randomised control trials examining the effectiveness of influenza vaccines for people with bronchiectasis revealed no relevant studies. In the absence of evidence, patients’ needs should be individualised and national guidelines be adhered to.

**BACKGROUND**

Bronchiectasis, previously termed an ‘orphan disease’ is increasingly recognized as a major cause of respiratory morbidity especially in developing countries (Karadag 2005, Karakoc 2001) and in pockets of affluent countries (Singleton 2000, Callahan 2002, Edwards 2003). The underlying aetiology of bronchiectasis varies from post recurrent respiratory infections to rare immune deficiencies. A variety of diseases including the common chronic obstructive pulmonary disease (COPD) (Patel 2004) and less common respiratory diseases (e.g. bronchiolitis obliterans (Chang 1998) and sarcoidosis (Lewis 2002)) and even non-primary respiratory (e.g. autoimmune) diseases may culminate in the development of bronchiectasis. The presence of bronchiectasis increases the morbidity and mortality of the underlying primary disease (Patel 2004, Lewis 2002, Keistinen 1997). For example, bronchiectasis has been reported in 29-50% of COPD (Patel 2004, O’Brien 2000) and when present, increases the severity (Patel 2004) and frequency (Gursel 2006) of respiratory exacerbations. Thus, management of the symptoms and severity of bronchiectasis is important.

The dominant symptoms and signs of bronchiectasis are productive or wet cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze or crepitations on auscultation). In the long term, pulmonary decline may occur (Keistinen 1997, Twiss 2006). Like patients with COPD, children and adults with bronchiectasis also suffer from recurrent acute exacerbations, some of which require hospitalised treatment. Effective management regimes for bronchiectasis aim to reduce the frequency and severity of respiratory exacerbations and the rate long term pulmonary decline. Based on Cole’s ‘vicious circle hypothesis’, microbial colonization/infection is important in the pathophysiology of bronchiectasis as it leads to bronchial obstruction and a normal or exaggerated inflammatory response (Cole 1986). Thus treatment modalities that prevent or limit respiratory infections would prevent or reduce respiratory decline. Respiratory infections also increase morbidity and reduces quality of life in those suffering bronchiectasis (Martinez-Garcia 2005). Theoretically prevention of influenza through the use of influenza vaccine would be a useful routine management modality for children and adults with bronchiectasis. Indeed yearly influenza vaccination is recommended for patients with bronchiectasis (Chang 2002).

Both inactivated and live attenuated (LAIV) influenza vaccine are now available. Both are annually modified trivalent vaccines with adjustments for each of the major circulating influenza viruses: A (H3N2), A (H1N1) and B and administered annually (Orenstein 2005). The efficacy is directly related to the degree of concordance between the virus strains included in the vaccine and the strains circulating in the community. The inactivated vaccine contains killed viruses and is administered via intramuscular route and is recommended in those 6 months and older, in healthy individuals and those with chronic medical conditions. The newer LAIV contains live virus with potential for replication and is currently only recommended in healthy individuals aged between 5 and 49 years (Orenstein 2005), thus contraindicated in those with bronchiectasis.

Current recommendations for inactivated influenza vaccination includes adults aged 65 years and over, those in residential care and health care workers and also all adults and children with chronic illness, particularly cardiac and pulmonary diseases. Influenza vaccine has been estimated to be 70-90% effective in preventing influenza in healthy individuals under 65 years of age, with some reduction in efficacy in the elderly (Orenstein 2005). A meta-analysis of 20 cohort studies involving both nursing home pop-
ulations and community-dwelling elderly estimated effectiveness of 56%, 53%, 50% and 68% for preventing respiratory illness, pneumonia, hospitalisation and death, respectively. The efficacy of influenza vaccination in children is less known, though it has been estimated to provide 56% or more protection (Orenstein 2005, Fukuda 2004). The effect of influenza vaccine in preventing asthma exacerbations related to influenza is uncertain in patients with asthma (Cates 2008). In another Cochrane review, Poole and colleagues concluded that influenza vaccination reduces respiratory exacerbations in patients with COPD (Poole 2006). The effect size described in the meta-analysis of RCTs was similar to that of observational studies (Poole 2006).

The triggers for bronchiectasis exacerbations are less well studied compared to the available data on triggers of exacerbations for asthma and COPD. The proportion of bronchiectasis exacerbations triggered by infections is uncertain, much less the culprit microbiological organism. The effectiveness of influenza vaccination for bronchiectasis may thus, be rather different to that for asthma and COPD. Influenza vaccination may be associated with local and systemic adverse events including a flu-like illness (Poole 2006). A systematic review of the effectiveness of influenza for children and adults with bronchiectasis would be beneficial to guide clinical practice.

**OBJECTIVES**

To evaluate the effectiveness of influenza vaccine as routine management in children and adults with bronchiectasis in (a) reducing the severity and frequency of respiratory exacerbations and (b) pulmonary decline

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

All randomised controlled trials using influenza vaccine in patients with bronchiectasis

**Types of participants**

Children or adults with bronchiectasis (defined clinically or radiologically)

Exclusion criteria: Participants with cystic fibrosis or other diseases where bronchiectasis is not present

**Types of interventions**

All randomised controlled trials with at least one annual influenza vaccine. All types of influenza vaccines were to be included.

**Types of outcome measures**

It was planned that attempts would have been made to obtain data on at least one of the following outcome measures:

A) for short-term effectiveness (12 months or less)
   a) proportions of participants who had respiratory exacerbations
   b) proportions of participants who were hospitalised,
   c) total numbers of days with respiratory symptoms
   d) total number of hospitalised days
   e) mean difference in bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc)
   f) proportions experiencing adverse effects of the intervention,
      (e.g. local reaction, exacerbation immediately post vaccination, systemic effects (myalgia, fever, fatigue), Gullian-Barre syndrome, etc)

Outcomes (a) to (e) were to be examined globally as well as also specifically to proven influenza infections (from swabs or rising titres)

B) for medium to long-term outcomes (>1 year)
   g) radiology scores (high resolution computed tomography scans or chest radiograph)
   h) lung function
   i) clinical indices of bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, etc).
   j) relevant airway markers of inflammation.

**Search methods for identification of studies**

Trials were identified from the following sources:

1. The Cochrane Airways Group Specialised Trials Register
2. The Cochrane Central Register of Controlled Trials (CENTRAL)
3. MEDLINE (1966 to present). Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.
4. OLDMEDLINE (1950 to 1965). Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.
5. EMBASE (1980 to present). Topic search strategy combined with the RCT search filter as outlined in the Airways Group module.
6. The list of references in relevant publications.
7. Written communication with the authors of trials would have been included in the review if necessary.
8. Pharmaceutical companies that manufacture influenza vaccines.
The search strategies used in the electronic databases are listed in Appendix 1. The latest searches were performed in July 2010.

### Data collection and analysis

#### Selection of studies

From the title, abstract, or descriptors, two reviewers independently reviewed literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, the same two reviewers independently selected trials for inclusion. Agreement would have been measured using kappa statistics. Disagreement would have been resolved by consensus.

#### Data extraction and management

It was planned that trials that satisfied the inclusion criteria would have been reviewed and the following information recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data would have been extracted on the outcomes described previously. Further information would have been requested from the authors when required.

#### Assessment of risk of bias in included studies

Studies included in the review would have undergone quality assessment performed independently by two reviewers. Four components of quality would have been assessed. Risk of bias in included studies would have been assessed as either high, low or unclear risk of bias using the Cochrane Collaboration’s risk of bias tool (Higgins 2008), and the following headings: 1) sequence generation; 2) allocation concealment; 3) blinding; 4) incomplete outcome data; 5) selective outcome reporting; 6) other bias. While only the allocation concealment quality assessment would have been displayed in the meta-analysis figures, all assessments would have been included in the “Characteristics of included studies” table. Inter-reviewer reliability for the identification of high quality studies for each component would have been measured by the Kappa statistic.

#### Measures of treatment effect

For the dichotomous outcome variables of each individual study, odds ratio (OR) would have been calculated using a modified intention-to-treat analysis. This analysis assumes that children not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies of all the individually analysed studies examine whether pooling of results (meta-analysis) is reasonable. This would take into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size.

#### Unit of analysis issues

For cross-over studies, mean treatment differences would have been calculated from raw data, extracted or imputed and entered as fixed effects generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. In cross-over trials, only data from the first arm would have been included in meta analysis if data were combined with parallel studies (Elbourne 2002).

#### Assessment of heterogeneity

Any heterogeneity between the study results would have been described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random effects model would have been calculated (Cochrane statistical package, Review Manager 5).

Numbers needed to treat (NNT) would have been calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003). If studies reported outcomes using different measurement scales, the standardised mean difference would have been estimated.

#### Data synthesis

It was planned that the results from studies that met the inclusion criteria and reported any of the outcomes of interest would have been included in the subsequent meta-analyses. The summary weighted risk ratio and 95% confidence interval (fixed effects model) would have been calculated (Cochrane statistical package, Review Manager 5).

#### Subgroup analysis and investigation of heterogeneity

The following a priori sub-group analyses were planned:

1. children (aged 18 years or less) and adults (>18 years)
2. types of influenza vaccine
3. type of control group
4. participant type (bronchiectasis as primary disease vs bronchiectasis as co-existent disease)
5. severity of bronchiectasis (based on lung function)

**Sensitivity analysis**

Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes:

1. study quality
2. study size
3. variation in the inclusion criteria
4. differences in the medications used in the intervention and comparison groups
5. differences in outcome measures
6. analysis using random effects model
7. analysis by "treatment received"
8. analysis by "intention-to-treat"

**RESULTS**

**Description of studies**

The searches identified four potential publications, none fulfilled the study eligibility criteria. The updated 2010 search identified 103 potential papers, one (Furumoto 2008) was retrieved but was excluded.

**Risk of bias in included studies**

Not applicable.

**Effects of interventions**

The Airways Group specialised register/search identified 289 potentially relevant titles. After assessing the abstracts, four publications were considered for inclusion into the review including two non-English articles (French). None of the studies fulfilled study criteria. No additional studies were found in the review articles. No additional data were available from the five pharmaceutical companies contacted (CSL Limited, Sanofi Pasteur Pty Limited, Chiron Vaccines Australia Pty Ltd, GlaxoSmithKline Australia Pty Ltd, Solvay Pharmaceuticals).

**DISCUSSION**

No randomised controlled trials comparing any influenza vaccines in children or adults with bronchiectasis were identified.

Based on many rationales including the risk factors of severe influenza infections, yearly influenza vaccination is widely recommended for patients with chronic respiratory disorders (Cosgrove 2005, Jefferson 2006). However there is no RCT evidence that has examined whether annual influenza vaccination is indeed beneficial in patients with bronchiectasis. The Cochrane review on influenza vaccination for patients with COPD described that “inactivated influenza vaccination has a clinically important and significant effect on influenza-related exacerbations, and probably an effect on the total of exacerbations in COPD patients” (Poole 2006). Given the wide overlap between COPD and bronchiectasis, where up to 50% of patients with COPD have coexistent bronchiectasis (Patel 2004), it is arguably justified that until new evidence to the contrary exist, patients with bronchiectasis should be routinely vaccinated. However influenza vaccinations are not without risks and adverse events although mostly minor, may be serious (Wong 2005). Thus, in the absence of good evidence for the benefits of annual routine influenza vaccination, individual preferences and risk factors for increased adverse events should be considered. Furthermore, the argument of policy versus evidence for influenza vaccination was recently elegantly discussed by Jefferson (Jefferson 2006).

In patients with asthma and COPD, Cochrane reviews have shown that inactivated influenza vaccinations do not cause an immediate respiratory exacerbation (Cates 2008, Poole 2006). Whether immediate respiratory exacerbations is increased in patients with bronchiectasis post inactivated influenza vaccinations is unknown; it remains a theoretical risk in the context of the common occurrence of mild immune dysfunction in patients with bronchiectasis (King 2006). In the consideration of possible future uses of LAIV (which is currently used only in healthy individuals and hence not currently relevant in this target group), the risk of viral shedding for several days, especially in children (Cosgrove 2005) must also be taken into account.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

There is neither evidence for nor against, routine annual influenza vaccination for children and adults with bronchiectasis from randomised controlled trials. Given the recommendations of the Cochrane review on influenza vaccination in patients with COPD (Poole 2006), and the significant overlap between COPD and bronchiectasis, current recommendations for annual influenza vaccination in patients with bronchiectasis is justified. However, individual responses and risk for adverse effects need to be taken into account when considered for routine annual influenza vaccination.
Implications for research

Acknowledging the difficulty in conducting large, randomised, placebo-controlled trials of repeated influenza vaccination in patients with bronchiectasis, it would still appear desirable to do so. There is also little knowledge on the effects of annual revaccination in this target group. Multi-centre randomised controlled trials to establish the efficacy of influenza vaccination in reducing severity and frequency of respiratory exacerbations and pulmonary decline in people with bronchiectasis are needed. As responses to vaccines alters with age, cohorts should comprise of different age groups including young children (aged under 2 years), children, adults and older adults. Determining true influenza infections from the range of other influenza-like illnesses by microbiological and serological techniques is recommended.

ACKNOWLEDGEMENTS

We thank Toby Lasserson and Chris Cates from the Airways Group for their advice, supportive role and comments to the protocol and review. We are also very grateful to Elizabeth Arnold for performing the relevant searches and obtaining the articles. We also thank Toby Lasserson for translation of the French articles.

REFERENCES

Furumoto 2008 [published data only]

Hayden 1995 [published data only]

King 2005 [published data only]

Lamotte 1981 [published data only]

Michel 1975 [published data only]

Callahan 2002

Cates 2003 [Computer program]

Cates 2008

Chang 1998

Chang 2002

Cole 1986

Cosgrove 2005

Edwards 2003

Elbourne 2002

Fukuda 2004
Gursel 2006

Higgins 2008

Jefferson 2006

Karadag 2005

Karadag 2001

Keistinen 1997

King 2006

Lewis 2002

Martinez-Garcia 2005

O’Brien 2000

Orenstein 2005

Patel 2004

Poole 2006

Singleton 2000

Twiss 2006

Wong 2005

* Indicates the major publication for the study.
## Characteristics of excluded studies  
[ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furumoto 2008</td>
<td>Study examined the clinical efficacy of combined vaccination with 23-valent pneumococcal vaccine and influenza vaccine (compared to influenza vaccine) against pneumonia and acute exacerbation of chronic lung diseases (CLD)</td>
</tr>
<tr>
<td>Hayden 1995</td>
<td>Pilot study to determine whether the use of structured guidelines for which pulmonary disorders warrant influenza vaccination increases use of vaccinations</td>
</tr>
<tr>
<td>King 2005</td>
<td>Observational study in adults with bronchiectasis</td>
</tr>
<tr>
<td>Lamotte 1981</td>
<td>Non RCT in French (review article)</td>
</tr>
<tr>
<td>Michel 1975</td>
<td>Study on children and adolescents with bronchiectasis using dietary supplements and anti-bacterial vaccine</td>
</tr>
</tbody>
</table>
## APPENDICES

### Appendix 1. Search strategies

<table>
<thead>
<tr>
<th>Central</th>
<th>Medline/Old medline</th>
<th>EMBASE</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1 MeSH descriptor Bronchiectasis explode all trees in MeSH products</td>
<td>1. exp bronchiectasis/</td>
<td>1. exp BRONCHIECTASIS/</td>
</tr>
<tr>
<td>#2 bronchiect*</td>
<td>2. bronchiect$.mp.</td>
<td>2. bronchiect$.mp.</td>
</tr>
<tr>
<td>#3 suppurativ* near lung*</td>
<td>3. (suppurativ$ adj5 lung$).mp.</td>
<td>3. (suppurativ$ adj5 lung$).mp.</td>
</tr>
<tr>
<td>#4 bronch* near dilat*</td>
<td>4. (bronch$ adj5 dilat$).mp.</td>
<td>4. (bronch$ adj5 dilat$).mp.</td>
</tr>
<tr>
<td>#5 (#1 OR #2 OR #3 OR #4)</td>
<td>5. or/1-4</td>
<td>5. or/1-4</td>
</tr>
<tr>
<td>#6 MeSH descriptor Influenza, Human explode all trees in MeSH products</td>
<td>6. exp Influenza Vaccines/</td>
<td>6. exp Influenza Vaccine/</td>
</tr>
<tr>
<td>#7 influenza*</td>
<td>7. flumist.mp.</td>
<td>7. flumist.mp.</td>
</tr>
<tr>
<td>#8 flu</td>
<td>8. trivalent.mp.</td>
<td>8. trivalent.mp.</td>
</tr>
<tr>
<td>#9 MeSH descriptor Influenza Vaccines explode all trees in MeSH products</td>
<td>9. LAIV.mp.</td>
<td>9. LAIV.mp.</td>
</tr>
<tr>
<td>#10 MeSH descriptor Immunization explode all trees in MeSH products</td>
<td>10. CAIV.mp.</td>
<td>10. CAIV.mp.</td>
</tr>
<tr>
<td>#11 MeSH descriptor Vaccines explode all trees in MeSH products</td>
<td>11. medimmune.mp.</td>
<td>11. medimmune.mp.</td>
</tr>
<tr>
<td>#12 vaccin*</td>
<td>12. exp Influenza/</td>
<td>12. exp Influenza/</td>
</tr>
<tr>
<td>#13 immuni*</td>
<td>13. influenza.mp.</td>
<td>13. influenza.mp.</td>
</tr>
<tr>
<td>#15 trivalent</td>
<td>15. exp immunization/</td>
<td>15. exp Vaccine/</td>
</tr>
<tr>
<td>#16 LAIV</td>
<td>16. exp vaccines/</td>
<td>16. exp immunization/</td>
</tr>
<tr>
<td>#17 medimmune</td>
<td>17. vaccinat$.mp.</td>
<td>17. vaccin$.mp.</td>
</tr>
<tr>
<td>#18 CAIV</td>
<td>18. immuni$.mp</td>
<td>18. immuni$.mp</td>
</tr>
<tr>
<td>#19 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)</td>
<td>19. or/6-18</td>
<td>19. or/6-18</td>
</tr>
<tr>
<td>#20 (#19 AND #5)</td>
<td>20. 19 and 5</td>
<td>20. 19 and 5</td>
</tr>
</tbody>
</table>

(Combined with RCT filter as described in 'About the Airways Group' on the Cochrane Library)
**WHAT'S NEW**

Last assessed as up-to-date: 19 July 2010.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>19 July 2010</td>
<td>New search has been performed</td>
<td>New search. No new studies added.</td>
</tr>
</tbody>
</table>

**HISTORY**

Protocol first published: Issue 4, 2006


<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 March 2009</td>
<td>Amended</td>
<td>Contact details changed.</td>
</tr>
<tr>
<td>16 April 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>18 April 2007</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment.</td>
</tr>
</tbody>
</table>

**CONTRIBUTIONS OF AUTHORS**

CC and AC wrote the protocol and review, and selected relevant articles from the search. CC wrote to the pharmaceutical companies. PM reviewed the manuscript.

**DECLARATIONS OF INTEREST**

None declared.

**INDEX TERMS**

Medical Subject Headings (MeSH)

Bronchiectasis [*complications]; Influenza Vaccines [*administration & dosage]; Influenza, Human [*prevention & control]
MeSH check words

Adult; Child; Humans